VANDA Pharmaceuticals - Investor Relations - IR Home

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vanda Pharmaceuticals Settles Fanapt® Patent Litigation with Apotex
WASHINGTON , Dec. 7, 2016 /PRNewswire/ -- Vanda Grants Apotex a license to sell generic Fanapt ® beginning November 2027 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it has entered into a License Agreement (the License Agreement) with Apotex Inc. and Apotex Corp.
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at November 2016 Investor Conferences
WASHINGTON , Nov. 14, 2016 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in November 2016 . The Stifel 2016 Healthcare Conference in New York City on Tuesday, November 15, 2016 .
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Third Quarter 2016 Financial Results
- Total revenues grew to $38.5 million, a 7% increase compared to the second quarter of 2016 and a 36% increase compared to the same period in 2015 WASHINGTON , Nov. 2, 2016 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today announced financial and operational results for
View HTML
Toggle Summary Vanda Pharmaceuticals Settles Fanapt® Patent Litigation with Taro
Vanda Grants Taro a license to sell generic Fanapt® beginning November 2027 WASHINGTON , Oct. 24, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it has entered into a License Agreement (the License Agreement) with Taro Pharmaceuticals U.S.A., Inc.
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 2, 2016
Conference Call and Webcast to Follow WASHINGTON , Oct. 12, 2016 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the third quarter of 2016 on Wednesday, November 2, 2016 , after the market closes.
View HTML
Toggle Summary USPTO Dismisses Petition for Inter Partes Review of Fanapt® Patent
WASHINGTON , Aug. 30, 2016 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board declined the request by Roxane Laboratories, Inc. (Roxane) to institute an inter partes review of
View HTML
Toggle Summary Vanda Patents Found Valid and Infringed in Fanapt® ANDA Litigation
WASHINGTON , Aug. 25, 2016 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that Judge Gregory M. Sleet of the United States District Court for the District of Delaware ruled that Roxane Laboratories Inc. (Roxane) infringed U.S. Patent Nos.
View HTML
Toggle Summary HETLIOZ® is Now Available for the Treatment of Non-24-Hour Sleep-Wake Disorder in Germany
- HETLIOZ® (tasimelteon) is the first and only product to receive approval for the treatment of Non-24 in the European Union WASHINGTON , Aug. 1, 2016 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that HETLIOZ® (tasimelteon) is now available for the treatment of
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results
HETLIOZ® net product sales grew to $17.5 million in the second quarter 2016 Fanapt® net product sales grew to $18.6 million in the second quarter 2016 Vanda reiterates 2016 net product sales guidance of $143 million to $153 million WASHINGTON , July 27, 2016 /PRNewswire/ -- Vanda Pharmaceuticals
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Second Quarter 2016 Financial Results on July 27, 2016
Conference Call and Webcast to Follow WASHINGTON , July 12, 2016 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2016 on Wednesday, July 27, 2016 , after the market closes.
View HTML
Toggle Summary Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
Presentation will be Webcast Live and Archived on Vanda's Website WASHINGTON , June 20, 2016 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that Mihael H. Polymeropoulos , M.D., Vanda's President and CEO, will deliver a corporate presentation at the JMP
View HTML
Toggle Summary FDA Grants Fanapt® Three Years of Marketing Exclusivity for Labeling Changes Relating to Maintenance Treatment of Schizophrenia
WASHINGTON , June 15, 2016 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration ( FDA ) has granted three years of marketing exclusivity for the changes related to the supplemental New Drug Application (sNDA) that was recently
View HTML
Toggle Summary Vanda Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
Presentation will be Webcast Live and Archived on Vanda's Website WASHINGTON , June 3, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that it will deliver a corporate presentation at the Jefferies Healthcare Conference in New York City on Thursday, June 9,
View HTML
Toggle Summary Vanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults
WASHINGTON , May 26, 2016 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration ( FDA ) has approved Vanda's supplemental New Drug Application (sNDA) for Fanapt ® , modifying and expanding the prescribing information (PI) to
View HTML
Toggle Summary Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results
- HETLIOZ® net product sales grew to $16.2 million in the first quarter 2016 - Fanapt® net product sales grew to $17.1 million in the first quarter 2016 - Vanda reiterates 2016 net product sales guidance of $143 million to $153 million WASHINGTON , May 4, 2016 /PRNewswire/ --  Vanda Pharmaceuticals
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 4, 2016
Conference Call and Webcast to Follow WASHINGTON , April 14, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2016 on Wednesday, May 4, 2016 , after the market closes.
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results
- HETLIOZ® net product sales grew to $15.1 million in the fourth quarter 2015 - Full year 2015 total revenues grew to $109.9 million WASHINGTON , Feb. 10, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter
View HTML
Toggle Summary Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day
WASHINGTON , Feb. 1, 2016 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel therapies addressing high unmet medical needs, today announced that members of its management team will participate in
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 10, 2016
Conference Call and Webcast to Follow WASHINGTON , Jan. 22, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth quarter of 2015 on Wednesday, February 10, 2016 , after the market closes.
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2015 Results and 2016 Financial Guidance
- Fourth quarter 2015 HETLIOZ® net product sales are expected to be approximately $15.1 million - 2015 Total revenues are expected to be approximately $109.9 million - 2016 Total revenues are expected to be between $143 and $153 million WASHINGTON , Jan.
View HTML
Copyright © 2005-2020 Vanda Pharmaceuticals Inc. |